COVID-19.Eli Lilly and Company announced the partial results Wednesday in a news release. "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories."Our teams have worked tirelessly the last seven months to discover and develop these potential antibody treatments," he added.Lilly has already started making one of the two antibodies in its drug, betting that ongoing studies would prove it worthwhile.Data from a new interim analysis of the BLAZE-1 clinical trial showed that combination.